Objective-High-mobility group box protein 1 (HMGB1) is a DNA-binding protein and cytokine highly expressed in atherosclerotic lesions, but its pathophysiological role in atherosclerosis is unknown. We investigated its role in the development of atherosclerosis in ApoEϪ/Ϫ mice. Methods and Results-Apolipoprotein E-deficient (ApoEϪ/Ϫ) mice fed a high-fat diet were administered a monoclonal anti-HMGB1 neutralizing antibody, and the effects on lesion size, immune cell accumulation, and proinflammatory mediators were assessed using Oil Red O, immunohistochemistry, and real-time polymerase chain reaction. As with human atherosclerotic lesions, lesions in ApoEϪ/Ϫ mice expressed HMGB1. Treatment with the neutralizing antibody attenuated atherosclerosis by 55%. Macrophage accumulation was reduced by 43%, and vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 expression was attenuated by 48% and 72%, respectively. CD11cϩ dendritic cells were reduced by 65%, and the mature (CD83ϩ) population was reduced by 60%. Treatment also reduced CD4ϩ cells by nearly 50%. mRNAs in lesions encoding tumor necrosis factor-␣ and interleukin-1␤ tended to be reduced. Mechanistically, HMGB1 stimulated macrophage migration in vitro and in vivo; in vivo, it markedly augmented the accumulation of F4/80ϩGr-1(Ly-6C)ϩ macrophages and also increased F4/80ϩCD11bϩ macrophage numbers. Conclusion-HMGB1 exerts proatherogenic effects augmenting lesion development by stimulating macrophage migration, modulating proinflammatory mediators, and encouraging the accumulation of immune and smooth muscle cells. (Arterioscler Thromb Vasc Biol. 2011;31:313-319.)
A therosclerosis is a chronic inflammatory disease characterized by intimal accumulation of atherogenic lipoproteins, extracellular matrix, smooth muscle cells, and inflammatory cells. Cytokines within atherosclerotic lesions play a key role in both the development and progression of atherosclerosis. 1, 2 Recently, we and others have identified a novel cytokine in human atherosclerotic lesions, high-mobility group box 1 (HMGB1), that could be important for regulating development of atherosclerosis. [3] [4] [5] HMGB1 has 2 main functions. As a nuclear protein, it stabilizes nucleosomes and bending of DNA, which facilitates gene transcription. It can also be released from necrotic cells 6 or secreted by inflammatory cells, such as macrophages, 3 and natural killer cells, 7 triggering inflammation. 8 HMGB1-nucleosome complexes released by necrotic cells activate macrophages and dendritic cells to produce cytokines, such as tumor necrosis factor ␣ (TNF-␣), interleukin-1␤ (IL-1␤), IL-6, and IL-10 9 ; also, native secreted HMGB1 stimulates monocytes to secrete proinflammatory cytokines. 10 With respect to the vasculature, HMGB1 stimulates the migration and proliferation of vascular smooth muscle cells 4, 11 and activates endothelial cells. 12 It induces the migration of macrophages, activates dendritic cells, 13, 14 and is required for dendritic cells maturation. 14, 15 Notably, dendritic cells control T-cell activation by secreting HMGB1. 16 Structurally, HMGB1 has a tripartite domain organization. It contains 2 similar DNA-binding domains, HMG Box A and Box B, and a unique C-terminal domain consisting of an acidic tail of 30 amino acids all connected by short amino acid sequences. 17 The proinflammatory activity of HMGB1 has been localized to Box B, and antibodies raised against Box B prevent HMGB1 actions 17, 18 ; a receptor for advanced glycation end products (RAGE)-binding domain is localized within the C-terminal component of Box B and the segment connecting to the acidic tail. 19 In contrast, Box A attenuates HMGB1-induced release of proinflammatory cytokines. 20, 21 The acidic tail is thought to be unstructured and interacts with specific basic residues in both boxes, possibly regulating their conformation. 22 The proinflammatory effects of HMGB1 have been attributed to its interaction with a number of receptor types, which appears dependent on factors bound to HMGB1. RAGE, toll-like receptor (TLR)2, and TLR4 appear to mediate proinflammatory effects in HMGB1-stimulated macrophages. 23, 24 HMGB1 in DNA immune complexes and nucleosome complexes appears to exert proinflammatory effects via TLR9 and TLR2, respectively. 12, 25 More recently, HMGB1 has also been shown to interact with CD24 and Siglec-10 to attenuate tissue damage induced immune responses 26 ; a balance between these and the detrimental effects of HMGB1 has been suggested to determine the overall magnitude of its detrimental effects. 26 HMGB1 has been implicated in a number of immunedriven diseases, including systemic lupus erythematosus, autoimmune diabetes, and arthritis. 9, 27, 28 In arthritis, it triggers inflammation by activating macrophages and inducing IL-1. 28 Because HMGB1 is overexpressed in atherosclerotic lesions [3] [4] [5] and activates immune processes that can augment atherosclerosis, 4, 11, [13] [14] [15] we examined its role in the development of atherosclerosis in apolipoprotein E-deficient mice (ApoEϪ/Ϫ mice). We used an anti-HMGB1neutralizing monoclonal antibody, which interacts specifically with the C-terminal sequence of HMGB1 within the acidic tail, to determine its role in atherosclerosis. This antibody reacts with HMGB1 and not HMGB2 and has been shown to inhibit HMGB1 responses in macrophages and ameliorates brain infarction induced by transient ischemia. 29 
Materials and Methods
Six-week-old ApoEϪ/Ϫ mice were fed a high-fat diet for 8 weeks and administered either an anti-HMGB1 monoclonal antibody or IgG2a control (400 g IV twice weekly). At the end of the study, mice were killed with an overdose of pentobarbitone, and blood, aortic sinus and arch, spleen, and lymph nodes were collected for histological and molecular studies. Monocyte proliferation in vivo was assessed after administering bromodeoxyuridine (1 mg IP) for 3 days before the mice were killed. The chemotactic effects of HMGB1 on monocytes was assessed in mice 5 hours after administering HMGB1 (20 g) into the peritoneal cavity.
A detailed Supplemental Methods section is available online at http://atvb.ahajournals.org.
Results

HMGB1 Expression in Atherosclerotic Lesions
HMGB1 is highly expressed in human atherosclerotic lesions, mostly by macrophages in which nearly 50% of the cells contained HMGB1 in their cytoplasm. 3 Therefore, we investigated whether atherosclerotic lesions in ApoEϪ/Ϫ mice also expressed HMGB1. HMGB1 was expressed within the aortic sinus of ApoEϪ/Ϫ mice and restricted to cells within the atherosclerotic intima ( Figure 1 ). HMGB1 appeared to be cell associated, frequently within the cytoplasm and also diffusely distributed within lesions; the latter most probably reflected secreted HMGB1 ( Figure 1 ).
Effect of HMGB1 Neutralization on Atherosclerotic Lesion Size
At 14 weeks of age (8 of weeks antibody treatment) total plasma cholesterol, low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol, and triglyceride levels were not different between mice treated with control or anti-HMGB1 neutralizing antibody ( Supplemental Table I ). However, analysis of Oil Red O-stained aortic sinus sections revealed significant differences in lipid deposition and atherosclerotic plaque size ( Figure 2 ). Morphometric analysis showed that the anti-HMGB1 neutralizing antibody reduced lesion size compared with treatment with control antibody, 89 253Ϯ13 098 m 2 versus 183 903Ϯ11 784 m (PϽ0.05; Figure 2 ). Similarly, macrophage accumulation was reduced in lesions of mice treated with the neutralizing antibody. Cross-sectional area of the aortic sinus that stained with anti-CD68 antibody averaged 83 400Ϯ15 451 m 2 in mice treated with the anti-HMGB1 neutralizing antibody compared with 141 364Ϯ12 608 m 2 with control antibody (Figure 2 ). To determine whether the effects of the HMGB1 antibody were due to neutralizing circulating HMGB1, we measured plasma HMGB1 levels in control and anti-HMGB1 antibody treated mice using a specific HMGB1 ELISA. Plasma HMGB1 levels were undetectable (Ͻ1 ng/mL) in both instances, similar to earlier reports in nonatherosclerotic mice, 30 suggesting that effects of the neutralizing antibody were local at the site of developing lesions.
Effect of Neutralizing HMGB1 on Atherosclerotic Lesion Composition
Analysis of atherosclerotic lesion composition also revealed differences between the 2 groups in terms of cellular composition. Because HMGB1 can stimulate the migration of dendritic cells, 14, 15 we investigated whether neutralizing HMGB1 activity attenuated their accumulation in developing lesions. Immunohistochemical studies and quantitative analysis indicated a marked reduction in dendritic cell accumu- Immunohistochemical identification of HMGB1 expression in aortic sinus atherosclerotic lesions in ApoEϪ/Ϫ mice. Left, HMGB1 (red staining) was localized within intimal cells (top insert) and also diffusely distributed within lesions (bottom inset). Cells within the media did not express HMGB1. Right, Region similar to that shown in A incubated with nonspecific rabbit IgG instead of the primary rabbit HMGB1 IgG. Section was counterstained with hematoxylin. Scale bar represents 100 m. lation, with CD11c staining averaging 8Ϯ1% of lesion area in aortic sinus of mice treated with anti-HMGB1 neutralizing antibody compared with 24Ϯ3% with control antibody (PϽ0.05; Figure 3 ). Because HMGB1 can also promote maturation of dendritic cells, 15 we investigated whether expression of CD83, a marker of dendritic cell maturation, was affected. CD83 expression in the lesions represented only a small fraction of the dendritic cell population, indicating that the dendritic cell population was largely immature (Figure 3 ). Treatment with the anti-HMGB1 antibody reduced the CD83 cell population by nearly 60% (PϽ0.05; Figure 3 ). Mature dendritic cells in atherosclerotic lesions are known to produce T-cell-attracting chemokines CCL19 and CCL21. 31 Consequently, we examined whether CD4ϩ T-cell accumulation was affected in mice treated with the anti-HMGB1 neutralizing antibody. Treatment with anti-HMGB1 neutralizing antibody reduced CD4ϩ T-cell accumulation in lesions by Ϸ50% (PϽ0.05; Figure 4 ). To determine the different T-cell subtypes that might be affected, we analyzed subset-specific mRNA expression. In lesions of anti-HMGB1 antibody-treated mice, we observed no change in expression of Tim-3, a known marker and negative regulator of Th1 lymphocytes (PϾ0.05; Figure 4) 32 ; Tim-1, a marker of Th2 lymphocytes, was undetectable ( Figure 4 ). 33 Because HMGB1 stimulates the in vitro migration and proliferation of vascular smooth muscle cells, 4, 11 and endothelial cells, 34 To further confirm that these cellular effects were largely restricted to developing atherosclerotic lesions, we also assessed lymphocyte populations in blood, spleen, and paraaortic lymph nodes. In these tissues anti-HMGB1 antibody treatment Figure II ). In addition, we assessed monoblast/promonocyte proliferation, as well as monocyte and dendritic cell numbers in blood of control and anti-HMGB1-treated mice and dendritic cell numbers in lymph nodes. Supplemental Table II) . Also, CD11c hi CD11b hi I-A b(hi) CD115 hi CD90 lo CD49b lo NK1.1 lo Ly-6G lo CD22 lo monocyte-derived dendritic cells in inguinal and mediastinal lymph nodes were unaltered by anti-HMGB1 antibody treatment; CD11cϩI-A b ϩCD115ϩ are thought to emigrate from lesions to lymph nodes during regression of lesions. 35 Together, these results indicate that monocytes/ dendritic cell numbers in blood do not account for the reduction in macrophages and dendritic cells in lesions of anti-HMGB1 treated mice. Similarly, emigration of dendritic cells from lesions does not appear to be affected by anti-HMGB1 antibody treatment.
HMGB1 Neutralization and Proinflammatory Mediators in Lesions
HMGB1 can increase the expression of a number of proinflammatory mediators including MCP-1, vascular cell adhesion molecule-1 (VCAM-1) and a variety of cytokines including IL-1␤, IL-6, and tumor necrosis-␣ (TNF-␣). 12, 36, 37 We investigated whether treatment with anti-HMGB1 neu-tralizing antibodies might affect expression of such proinflammatory mediators in developing lesions. Treatment with anti-HMGB1 neutralizing antibodies reduced expression of VCAM-1 in lesions by 50% and MCP-1 expression by nearly 70% (both PϽ0.05; Supplemental Figure III ). There also tended to be reductions in the expression of TNF-␣, IL-1␤, and interferon-␣, whereas IL-6 was unaffected (Supplemental Figure III ).
HMGB1 and Cell Migration
Because anti-HMGB1 antibody treatment affected immune cell accumulation in lesions, in particular macrophages, to a much greater extent than proinflammatory cytokines, we examined the possibility that HMGB1 might be influencing macrophage migration to developing lesions. In vitro, HMGB1 stimulates macrophage migration. 13 To confirm the chemoattractant actions of HMGB1 on mouse macrophages, we first assessed its ability to stimulate mouse RAW264.7 macrophage migration using 24-well chemotaxis chambers. HMGB1 stimulated their migration, more than doubling the number of migrated macrophages (PϽ0.05; Figure 5 ). To determine whether HMGB1 also stimulated macrophage cell migration in vivo, we injected HMGB1 into the peritoneal cavity of mice and 5 hours later assessed its effects on peritoneal macrophage. HMGB1 markedly increased the number of F4/80ϩGr1(Ly-6C)ϩ macrophages (PϽ0.05; Figure 5 ) and also increased F4/80ϩCD11bϩ macrophages (PϽ0.05; Figure 5 ).
Discussion
We have previously reported that HMGB1 is expressed by macrophages in human aortic fatty streaks and fibrofatty lesions. 3 In advanced atherosclerotic plaques, HMGB1 is also expressed by vascular smooth muscle cells. 5 Also, serum HMGB1 levels have been associated with coronary artery disease. 38, 39 In this study, we demonstrated that atherosclerotic lesions within the aortic sinus of ApoEϪ/Ϫ mice also express HMGB1, which contributes to lesion development. Neutralizing HMGB1 using a monoclonal antibody targeting amino acids within the acidic tail, 29 attenuated development of atherosclerosis. Our study suggests that HMGB1 in lesions rather than circulating HMGB1 contributes to atherosclerosis, stimulating macrophage migration and increasing the accumulation of other immune cell types, as well as proinflammatory mediators.
HMGB1 exerts multiple effects on monocyte/macrophages in vitro. It stimulates macrophage migration, 13 monocyte adherence and spreading, monocyte-matrix interactions, 40 and dendritic cell migration. 14 Our observations extend these findings and indicate that HMGB1 is also chemoattractive in vivo for macrophages; HMGB1 stimulated the migration of F4/80ϩGr-1(Ly-6C)ϩ macrophages, a subtype known to accumulate in atherosclerotic lesions. 41 It does not appear to influence monoblast/promonocyte proliferation, monocyte numbers in blood, or efflux of dendritic cells from lesions.
Our studies suggest that CD4ϩ T cells in lesions are also affected by HMGB1; CD4ϩ T-cell numbers were reduced in lesions of mice treated with the HMGB1 neutralizing antibody but unaffected in blood, spleen, or lymph nodes. In vitro HMGB1 acts as a costimulatory factor together with T-cell receptor stimulation to augment proliferation. 42 Also, dendritic cells produce and respond to HMGB1 elevating IL-12 secretion, which in turn polarizes CD4ϩ T cells to the Th1 phenotype. 37 Our finding that Tim-3 expression is unaffected by anti-HMGB1 antibody treatment, despite reductions in CD4ϩ T cells, suggests that the function of these cells may be impaired; Tim-3 is a negative regulator of Th1 cell function. 32, 43 Because HMGB1 appears to regulate immune cell numbers in lesions we also investigated whether it affected cytokine levels. In vitro, HMGB1 potently stimulates macrophages and endothelial cells to secrete proinflammatory cytokines, TNF-␣, IL-1␤, and IL-6. 12,37 Surprisingly, we found that neutralizing HMGB1 only had small effects on the expression of proinflammatory cytokines, suggesting that HMGB1 in lesions was affecting immune cell function rather than expression of proinflammatory cytokines in lesions. However, HMGB1 augmented the expression of proinflammatory mediators VCAM-1 and MCP-1.
In addition to affecting immune cells, HMGB1 can affect vascular smooth muscle cells, stimulating their migration 11 and proliferation. 4 Treatment with anti-HMGB1 neutralizing antibodies reduced smooth muscle cell accumulation and the number of proliferating cells within developing lesions. The intima is considered to be the "soil" in which atherosclerosis develops, 44 and attenuating its development/growth by neutralizing HMGB1 activity and reducing the intimal smooth muscle population could contribute to the reductions in lesion size. Although HMGB1 has also been shown to stimulate endothelial cell proliferation and angiogenesis, endothelial cells did not appear to be affected by treatment with the anti-HMGB1 neutralizing antibody.
Although our studies indicate that HMGB1 contributes to lesion development by stimulating macrophage migration and activating dendritic cells, the receptors through which these effects are mediated remain to be identified. It is interesting to note that the effects we observed on macrophages, dendritic cells, and T cells, as well as vascular smooth muscle cells, have been largely attributed to interactions with RAGE. 11, 13, 15, 16 Inhibition of RAGE attenuates lesion development and is associated with reductions in macrophage and smooth muscle cell accumulation, as well as reductions in VCAM-1 expression, 45 effects that we observed following neutralization of HMGB1. However, we cannot exclude the possibility that HMGB1 also interacts with other receptors during development of atherosclerosis, including TLR2, TLR4, or the CD24/Siglec-10 system. Our findings provide an encouraging basis for the development of a novel therapeutic approach for atherosclerosis, possibly using newer formats of recombinant antibodies.
In conclusion, our data extend earlier findings on the expression of HMGB1 in human atherosclerotic lesions and demonstrate that locally, 1 expressed HMGB contributes to lesion development by stimulating macrophage migration and modulating proinflammatory mediators such as MCP-1 and VCAM-1. HMGB1 also indirectly contributes to accumula- tion of dendritic cells and CD4ϩ T cells. The findings define a new potential therapeutic target for atherosclerosis.
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